Treatment Chart for Adult Patient with Suspected Wernicke Encephalopathy and Alcohol Withdrawal
Administer thiamine 500 mg IV immediately—before any glucose-containing fluids—to prevent precipitating acute Wernicke encephalopathy, then initiate symptom-triggered benzodiazepine therapy with long-acting agents for most patients or lorazepam if hepatic dysfunction is present. 1
Immediate Actions (Within First Hour)
Thiamine Administration – HIGHEST PRIORITY
- Give thiamine 500 mg IV immediately before any dextrose or glucose-containing fluids to treat suspected Wernicke encephalopathy 1, 2
- Continue thiamine 500 mg IV three times daily (1,500 mg/day total) for 3–5 days for suspected or proven Wernicke encephalopathy 1, 3
- After 3–5 days of IV therapy, transition to oral thiamine 100–300 mg/day and continue for 2–3 months after withdrawal resolution 1, 3
Critical Pitfall: Never administer glucose-containing IV fluids before thiamine, as this precipitates acute Wernicke encephalopathy in thiamine-depleted patients 1, 2, 3
Benzodiazepine Protocol – Symptom-Triggered Dosing
For patients WITHOUT hepatic dysfunction:
- Diazepam 10 mg IV/PO initially, then 5–10 mg every 3–4 hours as needed based on CIWA-Ar score 1
- Alternative: Chlordiazepoxide 50–100 mg PO loading dose, then 25–100 mg every 4–6 hours (maximum 300 mg in first 24 hours) 1
- Long-acting benzodiazepines provide superior protection against seizures and delirium tremens 1
For patients WITH hepatic dysfunction, elderly, or respiratory compromise:
- Lorazepam 2–4 mg PO/IV/IM every 4–6 hours (total 6–12 mg/day) 1
- Short-acting agents avoid drug accumulation in liver disease 1
Dosing trigger: Initiate benzodiazepines when CIWA-Ar ≥ 8; CIWA-Ar ≥ 15 indicates severe withdrawal requiring aggressive treatment 1
Duration limit: Taper and discontinue benzodiazepines by day 10–14 maximum to avoid iatrogenic dependence 1
Supportive Care & Electrolyte Replacement
Magnesium Supplementation
- Magnesium sulfate 2 g IV over 15 minutes, then 1–2 g IV every 6 hours for the first 24–48 hours 1
- Magnesium is commonly depleted in chronic alcohol use and is essential for thiamine-dependent enzymatic reactions 1, 4
Potassium Replacement
- Potassium chloride 20–40 mEq IV/PO every 4–6 hours to maintain serum potassium >3.5 mEq/L 1
- Monitor serum potassium every 6–12 hours during acute withdrawal 1
Folic Acid
- Folic acid 1 mg PO daily throughout withdrawal and for 2–3 months after resolution 2
Multivitamin
- Multivitamin 1 tablet PO daily containing B-complex vitamins 2
Fluid Replacement
- Normal saline or lactated Ringer's 1–2 liters IV over first 4–6 hours, then adjust based on vital signs and urine output 1
- Monitor for dehydration, electrolyte imbalance, and autonomic instability 1
Management of Agitation or Psychotic Symptoms
Low-Dose Antipsychotic (ONLY as Adjunct)
- Haloperidol 0.5–2 mg PO/IM every 8–12 hours for severe agitation or hallucinations not controlled by adequate benzodiazepine dosing 1, 2
- Alternative: Risperidone 0.5–2 mg PO every 8–12 hours 2
Critical Warning: Never use antipsychotics as monotherapy—they lower seizure threshold and worsen outcomes; they must only be added to adequate benzodiazepine therapy 1
Monitoring Protocol
Vital Signs & CIWA-Ar Assessment
- Assess vital signs and CIWA-Ar score every 1–2 hours during the first 24–48 hours 1
- Monitor for tachycardia, hypertension, fever, diaphoresis (autonomic instability) 1
- Continue monitoring every 4–6 hours until symptoms stabilize (typically day 3–5) 1
Complications Screening
- Evaluate daily for dehydration, electrolyte imbalance, infection, gastrointestinal bleeding, pancreatitis, hepatic encephalopathy, and renal failure 1
- Monitor for withdrawal seizures (peak risk 12–48 hours) and delirium tremens (peak risk 48–72 hours, days 3–5) 1
Benzodiazepine Taper (Starting Day 4–5)
Long-Acting Agents (Diazepam, Chlordiazepoxide)
- Begin taper after approximately 96 hours (day 4) when acute symptoms are improving 1
- Reduce daily dose by 25% every 2–3 days during the taper 1
- Complete discontinuation by day 10–14 1
Short-Acting Agents (Lorazepam, Oxazepam)
- After initial symptom control (3–5 days), decrease daily dose by 10–25% every 2–4 days 1
- Complete discontinuation by day 10–14 1
Monitoring during taper: Assess for rebound anxiety, tremor, autonomic hyperactivity, seizures, or altered mental status at each dose reduction 1
Post-Acute Management (After Day 7–14)
Mandatory Psychiatric Consultation
- Arrange psychiatric evaluation after withdrawal stabilization to assess alcohol-use disorder severity and plan long-term abstinence strategies 1, 2
Relapse-Prevention Pharmacotherapy (After Withdrawal Completion)
Preferred agents:
- Acamprosate ~2 g/day (safe in liver disease, reduces craving) 1, 2
- Baclofen up to 80 mg/day (the only medication with proven safety in cirrhotic patients) 1, 2
Contraindicated:
Alternative options:
Psychosocial Support
- Recommend participation in Alcoholics Anonymous or similar mutual-help groups 1
- Arrange motivational interviewing and structured psychological therapies 1
Summary Treatment Table
| Medication | Dose & Route | Frequency | Duration |
|---|---|---|---|
| Thiamine | 500 mg IV | Three times daily | 3–5 days, then 100–300 mg PO daily for 2–3 months [1,3] |
| Diazepam (no liver disease) | 10 mg IV/PO initially, then 5–10 mg | Every 3–4 hours PRN (CIWA-Ar ≥ 8) | Taper starting day 4; stop by day 10–14 [1] |
| Lorazepam (liver disease) | 2–4 mg IV/PO/IM | Every 4–6 hours PRN (CIWA-Ar ≥ 8) | Taper starting day 3–5; stop by day 10–14 [1] |
| Magnesium sulfate | 2 g IV loading, then 1–2 g IV | Every 6 hours | First 24–48 hours [1] |
| Potassium chloride | 20–40 mEq IV/PO | Every 4–6 hours PRN | Until K⁺ >3.5 mEq/L [1] |
| Folic acid | 1 mg PO | Daily | 2–3 months [2] |
| Multivitamin | 1 tablet PO | Daily | 2–3 months [2] |
| Haloperidol (if agitated) | 0.5–2 mg PO/IM | Every 8–12 hours PRN | Only as adjunct to benzodiazepines [1,2] |
| Normal saline | 1–2 liters IV | Over first 4–6 hours | Adjust based on clinical status [1] |
Critical Safety Checklist
✓ Thiamine BEFORE glucose 1, 2, 3
✓ Benzodiazepines are mandatory first-line (only proven therapy to prevent seizures and reduce mortality) 1
✓ Never use antipsychotics as monotherapy (they increase seizure risk) 1
✓ Limit benzodiazepines to ≤14 days total (avoid iatrogenic dependence) 1
✓ Avoid naltrexone in liver disease (hepatotoxicity risk) 1, 2
✓ Taper benzodiazepines gradually (never stop abruptly) 1